Steno-2研究事后分析:强化多因素治疗 vs 常规多因素治疗的成本分析
该事后分析基于Steno-2研究,比较160例丹麦2型糖尿病合并微量白蛋白尿患者接受强化或常规多因素目标驱动干预7.8年后的直接医疗成本。中位随访21.2年,两组总直接医疗成本无差异,但强化组人均年成本显著较低,主要因心血管疾病住院费用减少。
要点
- 强化多因素治疗7.8年未增加21.2年总直接医疗成本。
- 强化组人均年成本显著低于常规组,主因心血管住院费用减少。
- 结合寿命和健康获益,强化治疗在丹麦医疗体系中具有成本可行性。
核心结论
- 中位随访21.2年,强化与常规多因素治疗的总直接医疗成本无差异(p=0.48)。
- 强化组人均年成本显著较低(€8725 vs €10,091,p=0.045),主因心血管住院费用减少(p=0.0024)。
- 强化多因素治疗在高危2型糖尿病患者中平衡成本与获益具有高度可行性。
研究设计与样本
- Steno-2研究的事后分析,1993年纳入160例丹麦2型糖尿病合并微量白蛋白尿患者。
- 随机分配至常规或强化多因素目标驱动干预,干预持续7.8年。
- 直接医疗成本来自健康登记系统,采用bootstrap t检验比较组间成本。
主要发现
- 强化组总直接医疗成本€12,126,900,常规组€11,181,700,差异无统计学意义(p=0.48)。
- 1996-2014年人均年成本强化组€8725,常规组€10,091,差异显著(p=0.045)。
- 成本差异主要驱动因素为心血管疾病相关住院费用减少(p=0.0024)。
临床怎么用
- 对高危2型糖尿病患者,可考虑强化多因素目标驱动干预以改善长期结局且不增加总直接医疗成本。
- 强化治疗可能通过减少心血管住院费用降低人均年医疗成本。
局限性
- 为事后分析,非预先设定的成本效果分析。
- 成本数据基于丹麦医疗体系,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Long-term follow-up of the Steno-2 study demonstrated that intensified multifactorial intervention increased median lifespan by 7.9 years and delayed incident cardiovascular disease by a median of 8.1 years compared with conventional multifactorial intervention during 21.2 years of follow-up. In this post hoc analysis of data from the Steno-2 study, we aimed to study the difference in direct medical costs associated with conventional vs intensified treatment. METHODS: In 1993, 160 Danish individuals with type 2 diabetes and microalbuminuria were randomised to conventional or intensified multifactorial target-driven intervention for 7.8 years. Information on direct healthcare costs was retrieved from health registries, and the costs in the two groups of participants were compared by bootstrap t test analysis. RESULTS: Over 21.2 years of follow-up, there was no difference in total direct medical costs between the intensified treatment group, €12,126,900, and the conventional treatment group, €11,181,700 (p = 0.48). The mean cost per person-year during 1996-2014 was significantly lower in the intensified treatment group (€8725 in the intensive group and €10,091 in the conventional group, p = 0.045). The main driver of this difference was reduced costs associated with inpatient admissions related to cardiovascular disease (p = 0.0024). CONCLUSIONS/INTERPRETATION: Over a follow-up period of 21.2 years, we found no difference in total costs and reduced cost per person-year associated with intensified multifactorial treatment for 7.8 years compared with conventional multifactorial treatment. Considering the substantial gain in life-years and health benefits achieved with intensified treatment, we conclude that intensified multifaceted intervention in high-risk individuals with type 2 diabetes seems to be highly feasible when balancing healthcare costs and treatment benefits in a Danish healthcare setting.
引用
- Gæde J, Oellgaard J, Ibsen R, et al. A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study. Diabetologia. 2018. PMID: 30293113. doi:10.1007/s00125-018-4739-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。